OTLC
OTLC clinical trials: Oncotelic Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Oncotelic Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 3
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
OTLC on the catalyst calendar · OTLC registry changes
- Primary completion Jun 1, 2026Sponsor estimatePhase 2/Phase 3NCT06079346A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic CancerOncotelic Inc. · Pancreatic Ductal AdenocarcinomaRecruitingOTLCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT05425576OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint InhibitionOncotelic Inc. · Malignant Pleural MesotheliomaNot yet recruitingOTLCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2021Sponsor estimatePhase 2NCT04801017A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 SubjectsOncotelic Inc. · COVID-19Unknown statusOTLCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2028Sponsor estimatePhase 2NCT05935774OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerUniversity of Washington · Metastatic Lung Non-Small Cell CarcinomaWithdrawnOTLCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner